Orchestra BioMed’s Neuromodulation System Shows Promise in Long-Term Study
Orchestra BioMed reported that its BackBeat Cardiac Neuromodulation Therapy (CNT) system showed promise in a European clinical trial, in a presentation at the Transcatheter Cardiovascular Therapeutics 2022 annual conference in Boston, Mass.
BackBeat is a bioelectronic therapy candidate that is being developed in collaboration with Medtronic as a potential treatment for hypertension in patients who are indicated for a cardiac pacemaker. The collaboration deal was inked in June.
Following the trial’s initial 6-month period, 14 patients in the control group crossed over to the active BackBeat therapy. The long-term results in those patients were “consistent with the reductions in the BackBeat CNT group during the randomized portion of the study,” the company said.
The long-term results showed statistically significant reductions in ambulatory systolic blood pressure as well as meaningful reductions in office systolic blood pressure, the company said.